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BAFF, APRIL and their receptors: Structure, function and signaling
Claudia Bossen, Pascal Schneider ∗
Biochemistry Department, University of Lausanne, Boveresses 155, CH-1066 Epalinges, Switzerland
bstract
BAFF, APRIL and their receptors play important immunological roles, especially in the B cell arm of the immune system. A number of splice
soforms have been described for both ligands and receptors in this subfamily, some of which are conserved between mouse and human, while
thers are species-specific. Structural and mutational analyses have revealed key determinants of receptor–ligand specificity. BAFF-R has a strong
electivity for BAFF; BCMA has a higher affinity for APRIL than for BAFF, while TACI binds both ligands equally well. The molecular signaling
vents downstream of BAFF-R, BCMA and TACI are still incompletely characterized. Survival appears to be mediated by upregulation of Bcl-2
amily members through NF-B activation, degradation of the pro-apototic Bim protein, and control of subcellular localization of PCK. Very
ittle is known about other signaling events associated with receptor engagement by BAFF and APRIL that lead for example to B cell activation
r to CD40L-independent Ig switch.
2006 Elsevier Ltd. All rights reserved.
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. Introduction
The TNF family ligands APRIL (CD256, TNFSF13) [1] and
AFF (also known as BLyS, TALL-1, CD257 and TNFSF13B)
2–4] interact with three TNFR family members, TACI (CD267,
NFRSF13B) [5], BAFF-R (also known as BR3, CD268 or
NFRSF17) [6,7] and BCMA (CD269, TNFRSF13C) [8].
PRIL and TACI also bind independently to glycosaminogly-
an structures such as those present in syndecan-1 (CD138), or
ther proteoglycans [9–11].
The interaction pattern between BAFF, APRIL and their
eceptors is both specific and redundant: BAFF-R binds to BAFF,
CMA binds to APRIL, and TACI binds to BAFF and APRIL. In
ddition, BCMA binds BAFF with weaker affinity. Despite this
omplexity, the function of individual members of this subfamily
n the immune system is relatively well understood, in great part
s a result of the generation of a panel of mouse mutants. Recent
apers have reviewed these functions, e.g. [12–14]. The present
eview seeks to provide insight into three aspects of BAFF biol-
Abbreviations: APRIL, a proliferation-inducing ligand; BAFF, B cell acti-
ating factor of the TNF family; BAFF-R, BAFF receptor; BCMA, B cell matura-
ion antigen; TACI, transmembrane activator and CAML interactor; TRAF, TNF
eceptor-associated factor; TWEAK, TNF homologue with weak apoptosis-
nducing activity
∗ Corresponding author. Tel.: +41 21 692 5709; fax: +41 21 692 5705.
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he different members of the BAFF complex; binding specifici-
ies of BAFF-R, BCMA and TACI and the structural determi-
ants underlying ligand selectivity; and a summary overview of
he fragmentary information available concerning the signaling
athways engaged by BAFF and APRIL, in the context of their
nown functions.
.1. Splice variants of APRIL, BAFF and their receptors
.1.1. BAFF
The TNF family ligand BAFF is a Type II membrane-bound
rotein, which can be released as a soluble trimeric ligand upon
roteolytic processing at a furin consensus site. In the human
AFF gene, exon 1 codes for the transmembrane domain and
ts flanking regions, exon 2 for the furin processing site, and
xons 3–6 for the TNF homology domain (THD), which binds
o receptors (Figs. 1A and 2A).
At neutral or basic pH, 20 trimers of soluble recombinant
uman BAFF associate into a 60-mer virus-like structure, which
rreversibly dissociates into trimers at acidic pH, or when fused
o N-terminal extensions such as a myc tag [15,16] (Fig. 3C).
his association is dependent on an extended loop, known ashe “Flap”, that is unique to BAFF in the TNF family [15]
Fig. 3A and B). The physiological importance of the BAFF
0-mer is unclear, but it is a biologically active entity that can
ind receptors and is moderately more active than trimers in the
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Fig. 1. Genomic organization of BAFF, APRIL and their receptors. (A) BAFF and APRIL. (B) BAFF-R, BCMA and TACI. Exons are represented as boxes and
are shown to scale. The size of introns (thin line) and untranslated portions of the exons (UTR, thick lines) are not shown to scale. Alternative splicing events are
shown, and the name of the resulting protein is sometimes indicated. Alternative splice isoforms were detected by screening the NCBI database for non-redundant
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lnd EST sequences. Furin: sequence coding for a consensus furin processing sit
top codon. CRD: cysteine-rich domain (ligand-binding domain). UTR: 5′ and
n vitro assays [15,17]. Endogenously produced 60-mer BAFF
as recently been detected in supernatants of an histiocytic cell
ine [17].
The gene for mouse BAFF contains an additional exon encod-
ng a stretch of 30 amino acids located between the furin site
nd the THD (Fig. 1A). This extension is predicted to prevent
0-mer formation in the mouse, although this has not been for-
ally demonstrated. In both species, alternative splice variants,
n which exon 3 (exon 4 in the mouse) is skipped, generate an
n-frame deletion of the first -sheet of the THD to produce a
plice variant calledBAFF (Figs. 1A, 2 and 3A). The structural
mpact of this deletion is unknown, but does not seem to pre-
ent surface expression and heteromerization of BAFF with
AFF, yet appears to prevent release of the soluble form [18].
ransgenic mice expressing BAFF in myeloid and dendritic
ells display reduced B cell number and impaired T-dependent
umoral responses, consistent with BAFF being a dominant-
egative inhibitor of BAFF [19]. The splicing event in mouse
BAFF creates a functional N-linked glycosylation site [18],
hich is interesting in view of the fact that gain of glycosylation
a
a
[
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Immunology (2006), doi:10.1016/j.smim.2006.04.006.-R/K-R). THD: TNF homology domain. TMD: transmembrane domain. Stop:
ranslated regions.
an considerably affect the biological activity of extracellular
roteins [20].
Failure to splice intron 1 in human BAFF [18], or alternative
plicing to an acceptor site in intron 3 are relatively frequent
vents, but result in the production of no or prematurely termi-
ated BAFF protein (Figs. 1A and 2A).
.1.2. APRIL
The architecture of the APRIL gene resembles that of BAFF
Fig. 1). However, APRIL does not form 60-mers, but pos-
esses residues close to the furin processing site in exon 3
hat are crucial for binding to glycosaminoglycans (Fig. 2).
PRIL binds sulfated glycosaminoglycans at sites indepen-
ent from those used to bind other receptors [9,10]. The rel-
vance of this binding is unclear, but may serve to accumu-
ate and/or multimerize APRIL in the extracellular matrix or
t the surface of syndecan-positive cells. It thus may facilitate
ccess to its receptor TACI, which also interacts with syndecans
11], or to intracellular BCMA [21] upon syndecan internali-
ation.
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Fig. 2. Interactions of BAFF, APRIL and their receptors in the mouse and human. The main protein variants are schematized. Thick arrows depict high affinity
interactions, and thin arrows lower affinity interactions. Poorly characterized splice variants are shown at a scale of 50%. The number of EST sequences in the NCBI
database corresponding to the different variants is indicated (with sequences available in February 2006). These numbers represent sequences spanning 40 nucleotides
at relevant exon junctions (e.g. exons 1 and 2 for hAPRIL, and TWEAK exon 6 and APRIL exon 2 for hTWE-PRIL). Note that APRIL- does not correspond to
the published sequence (GenBank accession no. DQ149579 that does not conforms to a predicted product obtained by standard splicing events, but to that of an
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eST (GenBank accession no. BF793371). GBS: glycosaminoglycan-binding se
onserved region in BAFF-R and BCMA that binds to TRAF3.
A rare splicing event combines exon 1 of human APRIL to an
lternative acceptor site in exon 3, thus generating a predicted
embrane-bound, uncleavable human APRIL with no binding
o glycosaminoglycans (APRIL-) (Figs. 1A and 2A). Omission
f exon 3 yields APRIL-, an homologue of BAFF that also
acks the first -sheet of the THD [22], and by analogy with
BAFF may regulate APRIL activity in a dominant-negative
anner [18] (Figs. 1A, 2A and 4A). APRIL- is generated
y splicing of a cryptic intron in exon 6, resulting in a four
mino acids C-terminal truncation that is replaced by a sin-
le residue, but this isoform has not been further studied [22]
Figs. 1A, 2A and 4A). No similar sequences have been reported
r detected in ESTs of murine APRIL. Mouse APRIL does,
owever, exist as two variants differing by a single amino acid
Ala120) which are found at similar frequencies. This subtle
equence difference originates from alternative use of two splice
cceptor sites only three nucleotides apart at the beginning of
xon 4. A similar splicing event was previously reported in
nother TNF family member, EDA, whose variants differ by
wo amino acid residues only, yet display distinct receptor speci-
cities [23]. In the case of mouse APRIL, both variants bind
ACI and BCMA, and the only difference in receptor speci-
city was observed in the weak, but detectable, binding of the
s
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Immunology (2006), doi:10.1016/j.smim.2006.04.006.ce. THD: TNF homology domain. CRD: cysteine-rich domain. TRAF: highly
horter APRIL variant to mouse BAFF-R (unpublished data)
Fig. 2B). This weak binding is, however, only observed in the
ouse system and is unlikely to be physiologically relevant.
In both human and mouse genomes, the APRIL gene is
ocated immediately 3′ of TWEAK, another TNF family lig-
nd. An intergenic splicing event between exon 6 of TWEAK
nd exon 2 of APRIL generates human TWE-PRIL (Fig. 1A).
lthough this mRNA has been convincingly shown to exist
t abundances close to that of APRIL in T cells and various
ell lines [24], it is intriguing that there is currently no EST
equence in the NCBI database harboring this junction, whereas
STs coding for regular APRIL (in the corresponding region)
re abundant (Fig. 2A). However, mouse TWE-PRIL ESTs are
resent as two variants, with or without Ala120 (Fig. 2B). The
enesis of mouse TWE-PRIL is very different from that of its
uman orthologue, as it uses unique splice sites within exon 7
f TWEAK and within exon 1 of APRIL (Fig. 1A). Despite
his difference, both human and mouse TWE-PRIL contain the
ntire THD of APRIL, and are therefore expected to display the
ame receptor specificity as APRIL. Although TWE-PRIL has
wo furin consensus cleavage sites, the overexpressed form of
uman TWE-PRIL was resistant to cleavage, as was BAFF
18,24].
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Fig. 3. Structure of BAFF. (A) BAFF monomer in the ribbon representation. The sequence encoded by exon 2 (missing in BAFF) is shown in black. FLAP: D–E
loop implicated in 60-mer formation. (B) BAFF trimer. (C) BAFF 60-mer, with one trimer highlighted in black at the center of the structure. The arrangement of the
20 BAFF trimers in the dodecahedral structure is schematized below the actual structure. (D) BAFF trimer and BAFF-R monomer in surface representation, before
and after binding. One BAFF trimer can bind three receptors, each contacting a single monomer within the BAFF trimer. Models were drawn with PyMol, based on
coordinates files 1OQE and 1OTZ [31,32].
Fig. 4. Structure of APRIL. (A) APRIL monomer in ribbon representation. The sequences deleted in APRIL- and - variants are shown in black. (B) APRIL trimer.
(C) APRIL trimer and BCMA monomer in surface representation, before and after binding. An APRIL trimer can bind three receptors, each contacting a single
monomer within the APRIL trimer. Structures were drawn based on the atomic coordinate file 1XU2 [29].
Please cite this article as: Claudia Bossen, Pascal Schneider, BAFF, APRIL and their receptors: Structure, function and signaling, Seminars in
Immunology (2006), doi:10.1016/j.smim.2006.04.006.
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.1.3. BAFF-R and BCMA
BAFF-R and BCMA (and TACI) lack a signal peptide and
re therefore classified as Type III membrane proteins. Exon
encodes the ligand-binding domain (also called cysteine-rich
omain or CRD), exon 2 the transmembrane domain and flank-
ng regions, and exon 3 the intracellular domain (Fig. 1B).
he intracellular domains of both BAFF-R and BCMA are
trongly homologous over a short sequence of 18 amino acids,
hich in the case of BCMA contains a TRAF-binding consen-
us site (P/S/A/T-X-Q/E-E) (Fig. 2). BCMA is indeed known
o bind several TRAFs [25,26]. Although the TRAF signa-
ure is not conserved in BAFF-R, this region binds to TRAF3
ith high selectivity [27,28]. In the mutant A/WySnJ mouse,
4.7 kb gene insertion event disrupts the 3′ end of the BAFF-
gene, including part of this conserved sequence, leading to
efective BAFF-R signaling [7]. The use of alternative splice
onor and acceptor sites in exons 1 and 3, respectively, give
ise to different mouse BAFF-R isoforms. These insertions and
eletions occur outside the ligand and TRAF3 binding sites
Figs. 1B and 2B). Omission of exon 2 in human BCMA
enerates a predicted soluble receptor, but in the absence of
signal peptide, this protein is not expected to be secreted
Fig. 2A).
.1.4. TACI
The 3′ genomic organization of TACI is similar to that of
CMA and BAFF-R, but the ligand-binding region is dupli-
ated in an extra 5′ exon. This first ligand-binding domain has a
uch weaker affinity for BAFF and APRIL than the second one
29]. In human TACI only, an additional 5′ exon encodes a short
-terminal sequence. This often permits skipping of exon 2 to
roduce a short form of TACI lacking the first ligand-binding
omain. This short TACI binds BAFF and APRIL as efficiently
s the long form [29] (Figs. 1B and 2A). Human TACI is also
a
c
a
s
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inding affinities of BAFF and APRIL for BAFF-R, BCMA and TACI
eceptor Ligand Assay
AFF-R, monomer BAFF Compet. ELISA
AFF-R, monomer BAFF Compet. Biacore
AFF-R, monomer BAFF 3-mer Compet. Biacore
AFF-R, monomer BAFF 60-mer Compet. Biacore
CMA, monomer BAFF Compet. ELISA
CMA, monomer BAFF Compet. Biacore
CMA, monomer BAFF Compet. Biacore
ACI, monomer BAFF Compet. Biacore
ACIS, monomer BAFF Compet. Biacore
AFF-R, monomer APRIL Compet. Biacore
CMA, monomer APRIL Compet. Biacore
CMA, monomer APRIL Compet. ELISA
ACI, monomer APRIL Compet. Biacore
ACIS, monomer APRIL Compet. Biacore
AFF-R, dimer BAFF Compet. ELISA
AFF-R, dimer BAFF Compet. Biacore
CMA, dimer BAFF Compet. Biacore
CMA, dimer BAFF Compet. Biacore
AFF-R, dimer APRIL Compet. ELISA
CMA, dimer APRIL Compet. Biacore
ompet.: competition; app. aff.: apparent affinity.
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ubject to rarer intergenic splicing events removing the trans-
embrane and intracellular domains to yield soluble forms of
ACI. However, TACI being a Type III protein, these proteins
re not predicted to be secreted (Fig. 2A).
In mouse TACI, the initiating methionine and CRD1 are in
he same exon. Excision of CRD1 is not possible in mouse TACI
s it is in the human protein, because the 5′ non-coding exons
o not contain an ATG codon in frame with the exon containing
RD2 (Fig. 1B). However, one sequence of TACI indicates that
he reverse event can take place, i.e. deletion of the second CRD
fter splicing of a cryptic intron within exon 3 (Figs. 1B and 2B).
uriously, most mouse TACI transcripts start from within intron
and continue with exons encoding the transmembrane and
ntracellular portions of TACI. However, these transcripts lack
nitiating methionines and therefore should not encode proteins
Figs. 1B and 2B). It is not known if these transcripts regulate
ACI expression or fulfill other specific functions. A practical
utcome is that studies aimed at evaluating murine TACI expres-
ion at the RNA level will be influenced by the choice of RT-PCR
rimers.
In conclusion, conserved splicing events are relatively few
BAFF and to a certain extent TWE-PRIL). Most other splic-
ng events are species-specific, and therefore unlikely to play
ajor biological roles.
.2. Speciﬁcity of BAFF and APRIL interactions
Determining the true affinities of BAFF and APRIL for their
eceptors is not trivial. Indeed, measures performed with dimeric
eceptor–Ig proteins are subject to significant but unpredictable
vidity effects that increase the apparent affinity. The avidity
omponent is however removed by use of monomeric receptors,
nd results of such experiments are shown in Table 1. The con-
ensus is that, on the one hand, BAFF binds to BAFF-R and
Affinity nM Reference
IC50 92 [34]
KD 16 [99]
KD 15 [17]
KD 9 [17]
IC50 8000 [35]
KD Not detected [35]
KD 1600 [99]
IC50 1 [29]
IC50 2 [29]
KD Not detected [99]
KD 16 [99]
IC50 6 [35]
IC50 11 [29]
IC50 6 [29]
IC50 7 [35]
app. aff. <0.03 [99]
app. aff. 5 [35]
app. aff. 0.6 [99]
IC50 Not detected [35]
app. aff. 0.2 [35]
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ACI with affinities in the nanomolar range, yet displays two
o three order of magnitude weaker binding to BCMA. On the
ther hand, APRIL binds TACI and BCMA with high affinity
nanomolar range), but not at all to BAFF-R. When receptors
re dimerized as Ig fusion proteins, all receptors efficiently bind
igands in the low to subnanomolar range, with the exception of
AFF-R that does not bind to APRIL (Table 1, and reviewed in
30]). In comparison, APRIL binding to heparan sulfate proteo-
lycans is weak (20–80M) [30]. Whether endogenous BAFF
an signal through BCMA in vivo is not known, but will cer-
ainly depend on avidity effects. Clustering of membrane-bound
CMA, clustering of membrane-bound BAFF or occurrence of
ultimerized forms of soluble BAFF (60-mer), are potential fac-
ors that may affect the avidity of the BAFF–BCMA interaction
n vivo.
The molecular determinants of BAFF and APRIL specificity
or their receptors have been solved through a number of ele-
ant structural and mutational studies. BCMA and BAFF-R
iffer from other TNF receptor family members in that they
ossess a single cysteine-rich domain (CRD), which is used
o establish extensive contacts with a single ligand monomer
ithin BAFF or APRIL trimers [29,31,32] (Figs. 3D and 4C).
lthough TACI contains two CRDs, only the second one is
ecessary and sufficient for high affinity binding to BAFF and
PRIL, so that the mode of TACI interaction with APRIL and
AFF is essentially the same as that of BCMA or BAFF-R [29].
his is in sharp contrast to other family members that con-
ain up to four CRDs, and establish two main contact areas
t the interface between two ligand protomers (reviewed in
33]).
BCMA, TACI and BAFF-R show perfect structural conserva-
ion in a-hairpin structure that fits in a binding pocket of BAFF
nd APRIL and constitutes the conserved core of the interaction
Fig. 5). The hairpin structure is followed by a helix–loop–helix
a
m
ig. 5. Molecular basis for ligand-binding selectivity of TACI, BCMA and BAFF-R.
ide chains accounting for important positive or negative contributions to ligand bi
29,34,35]. A smiling face indicates that mutation of the residue impairs binding to the
hat the residue fails to provide a positive interaction, or is deleterious for ligand bin
he residue neither helps nor prevents ligand binding. The combined effect of these r
-terminal -hairpin and C-terminal helix–loop–helix structures are highlighted in th
OQD, 1OQE and 1XU1 [29,31].
Please cite this article as: Claudia Bossen, Pascal Schneider, BAFF, APRI
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otive that is strikingly different among receptors: its spatial
rientation differs in BCMA and TACI, independently of recep-
or binding, and BAFF-R contains only the first helix (Fig. 5).
n a first approximation, it can be said that the hairpin is cru-
ial for ligand binding, and that the C-terminal domain defines
igand specificity. Systematic mutagenesis studies of the ligand-
inding sequence of BAFF-R [34], BCMA [35] and TACI [29]
ed to the precise identification of residues dictating the lig-
nd specificity. For example, an aromatic residue in the hairpin,
resent in BCMA and TACI, but not BAFF-R, is absolutely
equired for APRIL binding, but dispensable for BAFF bind-
ng (Fig. 5, F78/Y13/C24). Introduction of this hydrophobic
esidue in BAFF-R confers binding to APRIL [31]. BAFF-R
ontains an hydrophobic residue (Leu38) that favors binding
o BAFF but is detrimental for APRIL, further explaining the
xquisite specificity of BAFF-R for BAFF and not APRIL
Fig. 5, P95/R27/L38). The corresponding position in BCMA is
ccupied by an arginine, which has the reverse effect, i.e. favor-
ng APRIL binding, but inhibiting the interaction with BAFF.
CMA also lacks an arginine in the hairpin that establishes
pecific contacts with BAFF but not APRIL, accounting for
he weak affinity of BAFF for BCMA (Fig. 5, R84/H19/R30).
uman BCMA contains an hydrophobic residue (Ile22) that
avors BAFF binding, but is not required for APRIL binding
Fig. 5, I87/I22/V33). Interestingly, mutation of this residue to
n arginine abrogates the BCMA–BAFF interaction without sig-
ificantly affecting binding to APRIL [35]. Finally, TACI does
ot present residues which are detrimental for APRIL or BAFF
inding, explaining its dual specificity [29]. However, the set of
esidues involved in BAFF or APRIL interaction with TACI is
artially different (Fig. 5).In conclusion, the complex binding specificities of the BAFF
nd APRIL ligands (Fig. 2) is now very well understood at the
olecular level.
Structure of receptor-binding domain of TACI, BCMA and BAFF-R. Selected
nding are shown. These side chains were identified by shotgun alanine scans
ligand (i.e. the residue contributes positively to the binding). Sad faces indicate
ding (i.e. mutation of the residue can improve binding). A dash indicates that
esidues on ligand binding (yes, weak, no) is also indicated. The location of the
e BCMA structure. Structures were drawn based on the atomic coordinate file
L and their receptors: Structure, function and signaling, Seminars in
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Fig. 6. Potential functions of APRIL and BAFF receptors in B cells. During development, B cells become dependent on signaling through BAFF at the transitional T1
stage. BAFF-R mediates a survival signal, whereas TACI acts as a negative regulator. BAFF-R is required for the formation of marginal zone B cells and upregulation
of CD21. During terminal differentiation, B cells become dependent on BCMA for survival. The dependence on the respective receptors correlates with increased
expression. Furthermore, in the context of T cell-independent responses, BAFF-R and TACI are likely important mediators of antibody class switching as these
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ctivation.
. Biological functions of receptors and signaling
athways
.1. BAFF-R and BCMA are involved in B cell survival
B cells enter the spleen at an immature T1 stage and further
ifferentiate through the immature T2 stage to either mature
r marginal zone B cells (Fig. 6). During differentiation, the
equirement for a functional B cell receptor (BCR) is high-
ighted in IgC mice [36]. The BCR consists of a surface
mmunoglobulin, which has no signaling capacity, and of Ig
nd Ig chains that signal through their cytoplasmic tails. Dele-
ion of the cytoplasmic tail of Ig (IgC) abrogates devel-
pment of B cells beyond the immature stage. In addition to
he BCR signal, a survival signal provided by BAFF is required
uring differentiation, and BAFF deletion results in greater than
0% loss of mature B cells [37,38]. This loss results from
educed survival at all stages beyond the immature T1 stage
39]. Initially, a maturation block at the T1 stage was reported
n BAFF−/− mice [37], but these conclusions were skewed as
hey relied on two markers, CD21 and CD23, whose expression
s regulated by BAFF [39]. Overexpression of the anti-apoptotic
roteins Bcl-2 or Bcl-xL in B cells of mice with deficient BAFF
unction significantly rescues B cell number, maturation and
unction, in line with a survival function for BAFF [40,41].
w
(
c
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Immunology (2006), doi:10.1016/j.smim.2006.04.006.CI and BAFF-R are also expressed on B-1 B cells and may play a role in their
owever, the partial rescue suggests that BAFF fulfills other,
on-survival functions. The receptor crucial for mediating BAFF
urvival signals at this stage is BAFF-R, as shown by loss of
ature B cells in BAFF-R mutant A/WySnJ mice [6,7]. The
esults were confirmed by deletion of BAFF-R [42,43]. At this
tage of B cell maturation, TACI acts as a negative regula-
or, because TACI−/− mice have a two to three-fold increased
umber of mature B cells [43–46]. BCMA is not implicated in
urvival of B cells at this stage of differentiation as BCMA−/−
ice have unaltered B cell numbers [37,47]. However, BCMA
s an important player at later stages of B cell differentiation
nd has been shown to be important for the survival of long-
ived bone marrow plasma cells [48] and likely for the survival
f plasmablasts [49]. This correlates with upregulated BCMA
xpression during terminal B cell differentiation [50]. As BCMA
inds APRIL with high affinity, the APRIL–BCMA axis might
redominate at later stages of B cell differentiation, or at least
artially replace the dependence for BAFF.
.2. Survival as a result of NF-κB activationDifferent aspects of the signaling downstream of BAFF-R,
hich leads to B cell survival, are beginning to be understood
Fig. 7). Activation of NF-B often correlates with survival out-
omes. Activation of dimeric NF-B transcription factors in B
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Fig. 7. Summary of signaling pathways downstream of BAFF receptors. The molecular events leading to survival, Ig switch or other responses downstream of
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hAFF-R, TACI and BCMA are in general poorly characterized. Dashed lines in
inks. For example, the inhibitory role of BAFF-R on TRAF3 remains speculati
ells proceeds either through the canonical, NEMO-dependent
athway, or through the alternative, NEMO-independent path-
ay [51]. The canonical pathway requires the IKK complex,
omposed of the kinases IKK and IKK, and of the essential
odulator NEMO. It can be activated by several proteins includ-
ng TRAF2, 5 and 6 [52], and yields NF-B dimers containing
he p50 subunit. The alternative pathway can be activated by
eceptors linked to the kinase NIK and requires IKK (but not
KK and NEMO). It is hallmarked by the inducible processing
f the NF-B2 p100 protein to the p52 fragment, a component
f NF-B dimers [51]. TRAF2 and 5, but not TRAF6, can also
articipate in the alternative pathway [53].
The importance of the alternative pathway downstream of
AFF-R has been demonstrated in vivo [54]. Mice deficient in
52 display a reduction in mature B cells. Bone marrow-derived
52-deficient transitional T1 B cells respond only very weakly
o BAFF. Similar results were obtained using cells from aly/aly
ice, which harbor an inactivating mutation in the NIK kinase.
he importance of IKK for B cell maturation is demonstrated
n vivo by IKK−/− bone marrow chimeras, which display a
eduction in mature B cells [55]. This reduction is however not
s strong as that observed in BAFF−/− mice. A penetrance of
cell depletion similar to that observed in BAFF or BAFF-R-
eficient mice is only observed in mice lacking components of
oth classical and alternative pathways, e.g. p52 and p50 [56].
here are two possible explanations: either p50 can compensate
o some extent for p52 loss in the alternative pathway, or BAFF-
activates both canonical and alternative pathways (Fig. 7).
hosphorylation of IB, which could reflect activation of the
anonical pathway, has been documented downstream of BAFF-
in mature, but not immature, B cells [57,58]. However, this
f
w
a
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e text for further details).
ctivation is weak compared to known activators of the classical
F-B pathway.
The molecular link between BAFF-R and the activation of
F-B is unclear. BAFF-R only binds to TRAF3, but to none of
he NF-B-activating TRAFs [27]. Analysis of the TRAF3 bind-
ng portion of BAFF-R co-crystallized with TRAF3 revealed
hat Gln379 of TRAF3, which is not conserved in TRAF2, is
mportant for this binding, providing a molecular basis for this
pecificity [28]. However, TRAF3 is not a positive regulator
f BAFF-R-mediated survival signals, because TRAF3−/− fetal
iver chimeras form B cells relatively normally [59]. In support
f this negative role, TRAF3 is also known to inhibit alterna-
ive NF-B activation by TRAF2 and 5 downstream of many
NF receptors [53]. An interesting concept was raised by Liao
t al. who showed that TRAF3 inactivates NIK in the M12 B
ell line, but that this inhibition is relieved by CD40 or BAFF-R
ignaling. In other words, BAFF-R would act as a repressor of
RAF3 [60]. This concept predicts both loss of B cell survival
pon disruption of the TRAF3/BAFF-R interaction, and survival
f B cells in the absence of TRAF3. However, BAFF-induced
RAF3 degradation was not confirmed in other cell types, and
ctivation of the alternative pathway was observed in mature B
ells following BAFF stimulation without (or with little) TRAF3
egradation [61]. It remains however possible that NIK may be
tabilized by recruitment to BAFF-R, with or without TRAF3,
nd signal despite the presence of TRAF3. In this respect, NIK
as been shown to be recruited to CD27, another TNF receptor
amily member [62].
Other TRAFs regulate the alternative NF-B pathway. Mice
ith B cell-specific TRAF2 deletion revealed TRAF2 as a neg-
tive regulator of the alternative pathway [61]. Mature B cells
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ccumulate in these mice and addition of BAFF cannot induce
urther generation of p52. As BAFF-R does not interact with
RAF2, it remains to be elucidated how TRAF2 inhibits the
lternative NF-B pathway downstream of BAFF-R.
Act1, an adaptor protein without enzymatic activity, was
rst described as an NF-B activator in the CD40 signaling
athway [58]. Generation of Act1−/− mice demonstrated that
ct1 actually functions as a negative regulator of both NF-
B pathways downstream of CD40 [63]. As these mice dis-
lay an accumulation of B cells, and because a recruitment
f Act1 to BAFF-R was observed, a negative role for Act1
ownstream of BAFF-R was postulated. Nevertheless, imma-
ure T1 B cells accumulate along with other splenic B cell
ubsets, arguing against a specific role of Act1 downstream of
AFF-R.
The identity of the relevant NF-B-regulated genes expressed
n response to BAFF-R signaling remains unsettled. BAFF
nduces upregulation of anti-apoptotic Bcl-2 members such as
cl-xL or Bcl-2, leading to survival [54,57]. Bcl-xL (but not Bcl-
) is a well-documented target of the classical NF-B pathway
64]. It is tempting to speculate that Bcl-2 might be a target of the
lternative pathway induced by BAFF in B cells [65]. Indeed,
cl-2 levels are reduced in p50−/−p52−/− and c-Rel−/−RelA−/−
ouble knock-out mice [56,66] and the Bcl-2 promoter contains
otential NF-B-binding sites [64,65,67]. Nevertheless, upreg-
lation of Bcl-2 after BAFF stimulation remains controversial
57,68]. Finally, the Bcl-2 family member A1 was also proposed
s a target of BAFF signaling [69], but these results were chal-
enged by data suggesting that A1 was a target of BCR signaling
nly [68].
.3. BAFF-R, TACI and T cells
In addition to its role in B cell survival, BAFF-R has also been
mplicated in T cell physiology. BAFF can costimulate prolifera-
ion of suboptimally stimulated T cells in a BAFF-R-dependent
nd TACI-independent manner [70,71]. The in vivo relevance
as demonstrated by studying cardiac allograft rejection. After
llograft transplantation, BAFF binding to BAFF-R in CD4+ T
ells costimulated alloproliferation and contributed to allograft
ejection [72]. Signaling in T cells has not been investigated to
ate, except for Bcl-2 upregulation in response to BAFF stimu-
ation [71].
Although TACI was first described as being expressed in T
ells [5], subsequent studies have shown that wild type murine
cells do not expresses more TACI than TACI−/− T cells [71].
f T cells express no TACI, how can it be that cytotoxic T lym-
hocyte (CTL) priming is severely compromised in TACI−/−
ice? [73]. B cells are required for CTL priming, but TACI−/−
cells cannot fulfill this function. Moreover, low amounts of
ACI–Ig could circumvent the need for B cells in CTL prim-
ng in vivo, suggesting the following scenario: TACI on B cells
inds to membrane-bound BAFF expressed on dendritic cells.
hrough a postulated reverse BAFF signaling, dendritic cells
ain the ability to prime CD8+ T cells (Fig. 7) [73]. It will be
nteresting to see if direct evidence of reverse signaling through
AFF can be obtained.
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.4. Activation of NF-κB by BCMA and TACI
The signaling of BCMA leading specifically to plasmablast
nd/or plasma cell survival has not been investigated, but may
nvolve similar signaling pathways as those induced by BAFF-
. In this regard, BCMA is a potent activator of the classical
F-B pathway [25,26,74], most probably through its ability to
ind members of the TRAF family. Two reports have described
CMA interaction with TRAF1, 2 and 3, or with TRAF5 and 6,
ut not 2, respectively [25,26].
In contrast to BCMA and BAFF-R, TACI is regarded as a
egative regulator of B cell survival [43–46], although it is a
otent activator of the classical NF-B signaling pathway and
an interact with TRAF2, 3, 5 and 6 [75]. In vitro studies have
hown that TACI can induce apoptotic signals in response to
gonistic antibody stimulation [46]. Regardless of intracellular
ignaling, TACI can also be cleaved [76] and might regulate B
ell survival indirectly through BAFF sequestration.
.5. Survival as a result of pro-apoptotic protein
egradation
BH3-only proteins are pro-apoptotic members of the Bcl-2
amily. This subgroup, which includes Bid, Bad, Bik, Bim, Bmf,
rk, Noxa and Puma, induces apoptosis by counteracting anti-
poptotic Bcl-2 family members. Bim is required for apoptosis
nd proper development of hematopoietic cells [77]. BCR stim-
lation in WEHI-231 mouse B cells and primary immature B
ells results in increased levels of the pro-apoptotic factor Bim
78]. Craxton et al. recently discovered that stimulation through
ither BAFF-R, TACI or BCMA leads to decreased Bim protein
evels [78]. Bim degradation requires MEK and Erk activation,
s shown by using a specific MEK inhibitor. The molecular
ink between the receptors and Erk activation was not inves-
igated. However, the relevance of Bim downstream of BAFF-R
s supported by genetic evidence: Bim−/− mice display an accu-
ulation of transitional T2 and mature B cells but transitional
1 B cells are not affected [79].
.6. Survival as a result of PKCδ sequestration out of the
ucleus
Nuclear accumulation of PKC induces death of self-reactive
cells through ill-defined mechanisms that are nevertheless
ufficient to prevent emergence of lupus-like autoimmune man-
festations [80]. PKC was identified as a potential target for
AFF signaling, as PKC-deficient mice display an enlarged
cell pool that shows reduced BAFF dependence for survival,
nd as BAFF signaling prevented nuclear accumulation of PKC
81]. Activation of the alternative NF-B pathway in response to
AFF was not impaired in PKC−/− mice [81]. Consistent with
his observation, B cells deficient in c-Myb that express lower
evels of BAFF-R are not fully able to prevent nuclear accumu-
ation of PKC following BAFF stimulation, leading to reduced
cell survival [82]. The molecular link between BAFF-R and
KC has not been investigated and a positive role of PKC
ownstream of TACI should not be excluded.
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.7. TACI and BAFF-R in the regulation of Ig switch
In order for immunoglobulin class switch recombination to
ccur, at least two signals are required. One is provided by
ytokines and the other is provided, in case of T-dependent
ntigens, by CD40. The importance of CD40 is highlighted in
D40−/− mice, which display severely reduced IgG1 and no IgE
evels in their serum [83]. Nevertheless, IgA serum levels are
nly slightly altered, indicating that CD40-independent signals
re important for class switch recombination to IgA. In human B
ells, APRIL and BAFF induce class switch recombination inde-
endently of CD40, as measured at the nucleic acid level and by
he upregulation of surface IgG and IgA [84]. Antibody secretion
equires BCR stimulation [84]. The BAFF receptors mediating
lass switch recombination, namely BAFF-R and TACI, were
dentified using mice deficient in TACI, BCMA or BAFF-R [85].
AFF-R can mediate class switch to IgG and IgE, and TACI to
gG, IgE and IgA. Class switch to IgE requires IL-4 [85,86].
ecretion of Ig in mice does not require BCR signaling as in
uman B cells, but relies on endogenously produced cytokines,
uch as IL-10.
Reduction in IgA serum levels was observed both in TACI-
eficient mice [45] and in one out of two strains of APRIL-
eficient mice [87,88]. Consistently, BAFF Tg mice have
nhanced IgA serum levels [89]. These data fit with a phys-
ological role of TACI in IgA class switch recombination in
he mouse. Recently patients affected with common variable
mmuno-deficiency (CVID) disorder have been identified with
eterozygous or homozygous TACI mutations [90,91]. These
atients have low levels of serum immunoglobulins, or selective
gA deficiency, but normal or increased B cell numbers [90,91].
nterestingly, the same mutation in the heterozygous state was
hown to yield either severe CVID or no symptoms in a brother
nd a sister, highlighting the requirement for other genetic or
nvironmental factors in the development of CVID [90].
TACI was originally identified for its ability to bind CAML
calcium-modulator and cyclophilin ligand) and subsequently
ctivate the transcription factor NF-AT [5,11]. It is intriguing
hat a TACI mutation discovered in CVID patients (R202H) lies
ithin the large and poorly defined CAML binding site. It is
owever not clear if this mutation would affect CAML signaling.
AML−/− mice are not viable [92], and specific ablation of
AML in T cells impairs T cell development [93]. The role and
elevance of NF-AT activation in B cells remains unknown.
Heterozygous mutations in BAFF-R have also been identified
n CVID patients, although these mutations were also found in
he control population, albeit at a lower frequency [94]. Thus,
ACI and/or BAFF-R are likely mediators of CD40-independent
lass switch recombination, which occurs mainly during a T
ell-independent response. As T cell-independent class switch
ccurs in splenic marginal zone or intestinal lamina propria B
ells [95], it is not surprising that TACI expression was not or
nly weakly detected in germinal center B cells from human
onsils [50,71].
The signaling pathway which accounts for induction of class
witch recombination downstream of the BAFF and APRIL
eceptors is not well described. In human B cells, BAFF
l
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timulation-induced class switch recombination in a p38- and
NK-dependent but Erk-independent manner [96]. Indeed, inhi-
ition of these pathways using specific inhibitors leads to a
eduction in class switch recombination. Involvement of NF-
B was not studied, nor was it determined which receptors were
esponsible for activating these signaling pathways.
.8. BAFF-R promotes expression of CD23 and of the B
ell co-receptor complex, and BCMA favors antigen
resentation
The B cell co-receptor complex, consisting of CD19, CD21
nd CD81, binds to complement C3. Opsonized antigens of
lood-borne pathogens can cross-link the BCR to the B cell
o-receptor, lowering the threshold of B cell activation and
llowing rapid, T-independent antibody production. BAFF may
nhance function of the B cell co-receptor complex, by allowing
xpression of CD21 [39], and upregulation and phosphoryla-
ion of CD19 [97]. Signaling through BAFF-R is required for
ormal CD21 and CD23 expression, although downregulation
f the surface markers is less pronounced in BAFF-R−/− mice
han in BAFF−/− mice, indicating that another receptor might
e important [43]. Nevertheless, ablation of TACI and BCMA
oes not affect CD21 and CD23 expression [43]. Interestingly,
D23 downregulation is observed in BAFF−/− and BAFF-R−/−
ice, but not in A/WySnJ mice [43], which express a mutant
AFF-R, nor in TACI–Ig transgenic mice [76], suggesting that
esidual signaling through BAFF-R might be enough to fulfill
his function. In the absence of TRAF2, CD21 is upregulated,
onsistent with TRAF2 being a negative regulator of BAFF-R
ignaling, whereas CD23 remains unaffected [61]. Upregulation
f CD19 has been proposed to occur through induction of the
cell-specific transcription factor Pax5/BSAP [97]. However,
egulation of the B cell co-receptor is not sufficient by itself to
ationalize the effects of BAFF on T-independent type II anti-
ody responses, as these responses are more severely impaired
n BAFF−/− and TACI−/− than in BAFFR−/− mice. B1 B cells
ight also be important contributors to T-I II responses. Consis-
ent with this idea, TACI is expressed on B1 B cells along with
AFF-R [43], and these cells are responsive to APRIL [98].
Signaling through BCMA was linked to enhanced antigen
resentation [74]. In primary B cells, BCMA expression can
e induced through IL-4 and -6. On these stimulated B cells,
CMA signaling led to expression of several surface molecules
nown to be important for antigen presentation, in an NF-B-
nd JNK-dependent manner [74]. This effect of BCMA is prob-
bly irrelevant in plasma cells that do not present antigen. In
he A20 B cell line, the authors detected JNK activation through
CMA only, in contrast with previous data, which showed that
ACI could activate JNK in the same cell line [75].
. Concluding remarksThe BAFF subfamily shows a fascinating complexity at the
evels of protein expression, ligand receptor interactions, signal-
ng and functional outcomes. The past few years have witnessed
onsiderable progress in our molecular understanding of ligand
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receptor specificity, and on the function of individual receptors.
Although key features of signaling events leading to B cell sur-
vival have been highlighted, we are still far away from a complete
molecular understanding of these signaling events. Providing a
clearer picture will be a challenge for studies in the coming
years.
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